Calhoun Cardiology Center, Department of Medicine, University of Connecticut Health Center MC-3944, 263 Farmington Avenue, Farmington, CT 06030-3944, USA.
J Consult Clin Psychol. 2012 Apr;80(2):276-85. doi: 10.1037/a0026883. Epub 2012 Jan 9.
Contingency management (CM) reduces drug use, but questions remain regarding optimal targets and magnitudes of reinforcement. We evaluated the efficacy of CM reinforcing attendance in patients who initiated treatment with cocaine-negative samples, and of higher magnitude abstinence-based CM in patients who began treatment positive.
Initially cocaine-negative patients (n = 333) were randomized to standard care (SC), SC + CM reinforcing submission of negative samples with $250 in prizes ($250Abs), or SC + CM reinforcing attendance ($250Att). Initially cocaine-positive patients (n = 109) were randomized to SC, $250Abs, or higher magnitude CM ($560Abs).
For initially cocaine-negative patients, $250Abs and $250Att were equally efficacious to SC in enhancing longest duration of abstinence (LDA); $250Att patients submitted lower proportions of negative samples when missing samples were considered missing, but these patients also attended more study sessions, provided more samples, and submitted a higher proportion of negative samples than SC patients when expected samples were analyzed, ps < .05. In initially cocaine-positive patients, both CM conditions increased proportions of negative samples relative to SC when missing samples were excluded from analyses, but only $560Abs was efficacious in increasing LDA and proportion of negative samples when expected samples were analyzed, ps < .05. Follow-ups revealed no differences among groups, but LDA was consistently associated with abstinence during follow-up, p < .05.
High magnitude abstinence-based reinforcement improved all abstinence outcomes in patients who began treatment while using cocaine. For patients initiating treatment abstinent, both attendance- and abstinence-based CM resulted in improvements on some measures.
应急管理(CM)可减少药物使用,但在最佳目标和强化幅度方面仍存在疑问。我们评估了在开始治疗时可卡因呈阴性样本的患者中强化就诊的 CM 的疗效,以及在开始治疗时呈阳性的患者中基于更高幅度的戒断的 CM 的疗效。
最初可卡因呈阴性的患者(n = 333)被随机分配到标准护理(SC)、SC + 用 250 美元的奖品强化提交阴性样本的 CM(250Abs)或 SC + 强化就诊的 CM(250Att)。最初可卡因呈阳性的患者(n = 109)被随机分配到 SC、250Abs 或更高幅度的 CM(560Abs)。
对于最初可卡因呈阴性的患者,250Abs 和 250Att 在增强最长无吸毒期(LDA)方面与 SC 同样有效;当考虑到缺失样本时,250Att 患者提交的阴性样本比例较低,但这些患者也参加了更多的研究课程,提供了更多的样本,并且当分析预期样本时,提交的阴性样本比例高于 SC 患者,p<.05。在最初可卡因呈阳性的患者中,当排除分析中的缺失样本时,两种 CM 条件都增加了阴性样本的比例,但只有 560Abs 在分析预期样本时增加了 LDA 和阴性样本的比例,p<.05。随访显示组间无差异,但 LDA 在随访期间始终与禁欲相关,p<.05。
基于更高幅度的戒断的强化在开始治疗时使用可卡因的患者中改善了所有戒断结果。对于开始治疗时已经禁欲的患者,基于就诊和基于戒断的 CM 都在某些指标上有所改善。